Navigate / search

GW, Hoth Therapeutics Sign Sponsored Research Agreement

Person holding elbow

Biopharmaceutical company Hoth Therapeutics, Inc., which is focused on unique targeted therapeutics for patients suffering from conditions such as atopic dermatitis, has entered into a sponsored research agreement with the George Washington University (GW) to explore the use of Aprepitant for topical and/or systemic therapy to counter the dermatological related side-effects of Erlotinib therapy in cancer patients.